系统免疫炎症指数与胰腺癌预后的相关性

周发权; 陈师; 孙红玉; 汤礼军

doi:10.3969/j.issn.1001-5256.2022.11.046

系统免疫炎症指数与胰腺癌预后的相关性

DOI: 10.3969/j.issn.1001-5256.2022.11.046

周发权^{1, 2},
陈师³,
孙红玉²,
汤礼军^2, , ,

1.
川北医学院临床医学院，四川南充 637000
2.
中国人民解放军西部战区总医院普通外科，成都 610083
3.
四川大学灾后重建与管理学院，成都 610207

基金项目:

国家临床重点专科建设基金资助项目 (41732113)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：周发权、陈师负责文献检索，撰写文章；孙红玉、汤礼军负责指导撰写文章并最后定稿。

详细信息

通信作者:
汤礼军，tanglj2016@163.com

计量
- 文章访问数: 377
- HTML全文浏览量: 342
- PDF下载量: 34
- 被引次数: 0
出版历程
- 收稿日期: 2022-03-14
- 录用日期: 2022-05-12
- 出版日期: 2022-11-20

Correlation of systemic immune-inflammation index and pancreatic cancer prognosis, recent research progress

Faquan ZHOU^{1, 2},
Shi CHEN³,
Hongyu SUN²,
Lijun TANG^{2
, ,
,}

1.
College of Clinical Medical, North Sichuan Medical College, Nanchong, Sichuan 637000, China
2.
The PLA Center of General Surgery, General Hospital of Western Theater Command, Chengdu 610083, China
3.
Institute for Disaster Management and Reconstruction, Sichuan University, Chengdu 610207, China

Research funding:

National Clinical Key Subject of China (41732113)

More Information

Corresponding author: TANG Lijun, tanglj2016@163.com(ORCID: 0000-0001-6000-9515)

摘要

摘要: 炎症广泛参与肿瘤的发生与发展，对胰腺癌进展起着至关重要的作用。同时炎性细胞是构成肿瘤微环境的一部分, 在促进肿瘤细胞的增殖和侵袭性转移起着关键作用。近年来，越来越多的研究探讨以中性粒细胞、淋巴细胞和血小板为基础的系统免疫炎症指数与恶性肿瘤患者预后的关系，其中也包括对胰腺癌的研究。本文通过阐述系统免疫炎症指数与胰腺癌患者预后的关系，为制订适当的胰腺癌治疗策略提供参考。
- 胰腺肿瘤 /
- 系统免疫炎症指数 /
- 预后
Abstract: Inflammation is associated with cancer development and plays a crucial role in pancreatic cancer progression. Inflammatory cell infiltration in the tumor lesion is a part of the tumor microenvironment, which could promote tumor cell proliferation, invasion, and metastasis. Recently developed systemic immune-inflammation index (SII) based on level of neutrophils, lymphocytes, and platelets was used to predict prognosis of cancer patients, including pancreatic cancer patients. This review summarized and discussed recent research progress on correlation of systemic immune-inflammation index and pancreatic cancer prognosis to provide appropriate treatment selections.
- Pancreatic Neoplasms /
- Systemic Immune-Inflammation Index /
- Prognosis

HTML全文

参考文献(43)

[1]	ZHU XZ, LI H, XU HX, et al. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021[J]. China Oncol, 2022, 32(1): 1-12. DOI: 10.19401/j.cnki.1007-3639.2022.01.001. 朱鑫哲, 李浩, 徐华祥, 等. 2021年胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2022, 32(1): 1-12. DOI: 10.19401/j.cnki.1007-3639.2022.01.001.
[2]	RAHIB L, SMITH BD, AIZENBERG R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States[J]. Cancer Res, 2014, 74(11): 2913-2921. DOI: 10.1158/0008-5472.CAN-14-0155.
[3]	OKITSU K, KANDA T, IMAZEKI F, et al. Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer[J]. Genes Cancer, 2010, 1(8): 859-867. DOI: 10.1177/1947601910383417.
[4]	GUERRA C, COLLADO M, NAVAS C, et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence[J]. Cancer Cell, 2011, 19(6): 728-739. DOI: 10.1016/j.ccr.2011.05.011.
[5]	GUERRA C, SCHUHMACHER AJ, CAÑAMERO M, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice[J]. Cancer Cell, 2007, 11(3): 291-302. DOI: 10.1016/j.ccr.2007.01.012.
[6]	KIRKEGÅRD J, MORTENSEN FV, CRONIN-FENTON D. Chronic pancreatitis and pancreatic cancer risk: a systematic review and Meta-analysis[J]. Am J Gastroenterol, 2017, 112(9): 1366-1372. DOI: 10.1038/ajg.2017.218.
[7]	EVANS A, COSTELLO E. The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion[J]. Front Physiol, 2012, 3: 270. DOI: 10.3389/fphys.2012.00270.
[8]	WANG C, NING K, HU HH, et al. Research progress in tumor microenvironment of pancreatic cancer[J]. Chin J Dig Surg, 2020, 19(1): 109-112. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.018. 王超, 宁克, 胡欢欢, 等. 胰腺癌肿瘤微环境的研究进展[J]. 中华消化外科杂志, 2020, 19(1): 109-112. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.018.
[9]	AZIZ MH, SIDERAS K, AZIZ NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study[J]. Ann Surg, 2019, 270(1): 139-146. DOI: 10.1097/SLA.0000000000002660.
[10]	ZHANG SS. Clinicopathological features and outcomes of pancreatic cancer/Hsa_circ_0007564: a novel diagnostic and prognostic marker for pancreatic cancer[D]. Beijing: Peking Union Medical College, 2018. 张水生. 胰腺癌临床病理特点及预后/Hsa_circ_0007564: 胰腺癌诊断和预后新的标志物[D]. 北京: 北京协和医学院, 2018.
[11]	ZHANG K, HUA YQ, WANG D, et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer[J]. J Transl Med, 2019, 17(1): 30. DOI: 10.1186/s12967-019-1782-x.
[12]	Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association. Guidelines for the diagnosis and treatment of pancreatic cancer in China(2021)[J]. Chin J Dig Surg, 2021, 20(7): 713-729. DOI: 10.3760/cma.j.cn115610-20210618-00289. 中华医学会外科学分会胰腺外科学组. 中国胰腺癌诊治指南(2021)[J]. 中华消化外科杂志, 2021, 20(7): 713-729. DOI: 10.3760/cma.j.cn115610-20210618-00289.
[13]	ZHAO Y, CHENG J. Relationship between the systemic immune-inflammation index and the prognosis of pancreatic ductal adenocarcinoma patients after neoadjuvant chemotherapy[J]. Chin J Oncol Prev Treat, 2020, 12(2): 222-227. DOI: 10.3969/j.issn.1674-5671.2020.02.21. 赵阳, 程静. 系统免疫炎症指数与接受新辅助化疗胰腺导管腺癌患者预后的关系[J]. 中国癌症防治杂志, 2020, 12(2): 222-227. DOI: 10.3969/j.issn.1674-5671.2020.02.21.
[14]	MURTHY P, ZENATI MS, AL ABBAS AI, et al. Prognostic value of the systemic immune-inflammation index (SⅡ) after neoadjuvant therapy for patients with resected pancreatic cancer[J]. Ann Surg Oncol, 2020, 27(3): 898-906. DOI: 10.1245/s10434-019-08094-0.
[15]	SHANG J, HAN X, ZHA H, et al. Systemic immune-inflammation index and changes of neutrophil-lymphocyte ratio as prognostic biomarkers for patients with pancreatic cancer treated with immune checkpoint blockade[J]. Front Oncol, 2021, 11: 585271. DOI: 10.3389/fonc.2021.585271.
[16]	ZHOU FQ, CHEN S, SUN HY, et al. Prognostic value of the systemic immune-inflammation index in patients with pancreatic cancer: a systematic review and Meta-analysis[J]. Chin J Gen Surg, 2020, 29(9): 1076-1083. DOI: 10.7659/j.issn.1005-6947.2020.09.007. 周发权, 陈师, 孙红玉, 等. 系统免疫炎症指数与胰腺癌患者预后关系的系统评价和Meta分析[J]. 中国普通外科杂志, 2020, 29(9): 1076-1083. DOI: 10.7659/j.issn.1005-6947.2020.09.007.
[17]	LI X, LIN H, OUYANG R, et al. Prognostic significance of the systemic immune-inflammation index in pancreatic carcinoma patients: a meta-analysis[J]. Biosci Rep, 2021, 41(8): BSR20204401. DOI: 10.1042/BSR20204401.
[18]	DINH HQ, EGGERT T, MEYER MA, et al. Coexpression of CD71 and CD117 identifies an early unipotent neutrophil progenitor population in human bone marrow[J]. Immunity, 2020, 53(2): 319-334. e6. DOI: 10.1016/j.immuni.2020.07.017.
[19]	FRIDLENDER ZG, SUN J, KIM S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN[J]. Cancer Cell, 2009, 16(3): 183-194. DOI: 10.1016/j.ccr.2009.06.017.
[20]	SHOJAEI F, WU X, ZHONG C, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis[J]. Nature, 2007, 450(7171): 825-831. DOI: 10.1038/nature06348.
[21]	INO Y, YAMAZAKI-ITOH R, SHIMADA K, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer[J]. Br J Cancer, 2013, 108(4): 914-923. DOI: 10.1038/bjc.2013.32.
[22]	NIELSEN SR, STRØBECH JE, HORTON ER, et al. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade[J]. Nat Commun, 2021, 12(1): 3414. DOI: 10.1038/s41467-021-23731-7.
[23]	WANG QQ, ZHENG JY, NI QC, et al. Prognostic significance of CXCR2 expression in pancreatic ductal carcinoma[J]. Natl Med J China, 2014, 94(48): 3805-3808. DOI: 10.3760/cma.j.issn.0376-2491.2014.48.004. 王庆庆, 郑金榆, 倪启超, 等. CXCR2在胰腺导管癌组织中的表达与患者预后关系[J]. 中华医学杂志, 2014, 94(48): 3805-3808. DOI: 10.3760/cma.j.issn.0376-2491.2014.48.004.
[24]	HOSOI F, IZUMI H, KAWAHARA A, et al. N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of kappaB kinase beta expression[J]. Cancer Res, 2009, 69(12): 4983-4991. DOI: 10.1158/0008-5472.CAN-08-4882.
[25]	JUNG HS, GU J, KIM JE, et al. Cancer cell-induced neutrophil extracellular traps promote both hypercoagulability and cancer progression[J]. PLoS One, 2019, 14(4): e0216055. DOI: 10.1371/journal.pone.0216055.
[26]	ALBRENGUES J, SHIELDS MA, NG D, et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice[J]. Science, 2018, 361(6409): eaao4227. DOI: 10.1126/science.aao4227.
[27]	STEELE CW, KARIM SA, LEACH J, et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma[J]. Cancer Cell, 2016, 29(6): 832-845. DOI: 10.1016/j.ccell.2016.04.014.
[28]	JIN W, YIN H, LI H, et al. Neutrophil extracellular DNA traps promote pancreatic cancer cells migration and invasion by activating EGFR/ERK pathway[J]. J Cell Mol Med, 2021, 25(12): 5443-5456. DOI: 10.1111/jcmm.16555.
[29]	TAKEMOTO A, MIYATA K, FUJITA N. Platelet-activating factor podoplanin: from discovery to drug development[J]. Cancer Metastasis Rev, 2017, 36(2): 225-234. DOI: 10.1007/s10555-017-9672-2.
[30]	OBERMEIER HL, RIEDL J, AY C, et al. The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study[J]. Res Pract Thromb Haemost, 2019, 3(3): 503-514. DOI: 10.1002/rth2.12197.
[31]	SABRKHANY S, KUIJPERS M, KNOL JC, et al. Exploration of the platelet proteome in patients with early-stage cancer[J]. J Proteomics, 2018, 177: 65-74. DOI: 10.1016/j.jprot.2018.02.011.
[32]	DUAN B, HU J, LIU H, et al. Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk[J]. Int J Cancer, 2018, 142(7): 1322-1331. DOI: 10.1002/ijc.31171.
[33]	MITRUGNO A, SYLMAN JL, NGO AT, et al. Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC[J]. Am J Physiol Cell Physiol, 2017, 312(2): C176-C189. DOI: 10.1152/ajpcell.00196.2016.
[34]	ELASKALANI O, FALASCA M, MORAN N, et al. The role of platelet-derived ADP and ATP in promoting pancreatic cancer cell survival and gemcitabine resistance[J]. Cancers (Basel), 2017, 9(10): 142. DOI: 10.3390/cancers9100142.
[35]	KHORANA AA, HU YC, RYAN CK, et al. Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer[J]. J Gastrointest Surg, 2005, 9(7): 903-911. DOI: 10.1016/j.gassur.2005.06.021.
[36]	JIMENEZ RE, HARTWIG W, ANTONIU BA, et al. Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control[J]. Ann Surg, 2000, 231(5): 644-654. DOI: 10.1097/00000658-200005000-00004.
[37]	MIYASHITA T, TAJIMA H, MAKINO I, et al. Metastasis-promoting role of extravasated platelet activation in tumor[J]. J Surg Res, 2015, 193(1): 289-294. DOI: 10.1016/j.jss.2014.07.037.
[38]	JANG JE, HAJDU CH, LIOT C, et al. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer[J]. Cell Rep, 2017, 20(3): 558-571. DOI: 10.1016/j.celrep.2017.06.062.
[39]	CARSTENS JL, CORREA DE SAMPAIO P, YANG D, et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer[J]. Nat Commun, 2017, 8: 15095. DOI: 10.1038/ncomms15095.
[40]	LI J, BYRNE KT, YAN F, et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy[J]. Immunity, 2018, 49(1): 178-193. e7. DOI: 10.1016/j.immuni.2018.06.006.
[41]	CASTINO GF, CORTESE N, CAPRETTI G, et al. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma[J]. Oncoimmunology, 2016, 5(4): e1085147. DOI: 10.1080/2162402X.2015.1085147.
[42]	LEE HS, LEEM G, KANG H, et al. Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma[J]. J Gastroenterol Hepatol, 2021, 36(2): 516-522. DOI: 10.1111/jgh.15265.
[43]	LIN M, LIANG S, WANG X, et al. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage Ⅲ/IV) pancreatic cancer: a promising treatment[J]. J Cancer Res Clin Oncol, 2017, 143(12): 2607-2618. DOI: 10.1007/s00432-017-2513-4.